Yüklüyor......
Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
Checkpoint inhibitors were a major breakthrough in the field of oncology. In September 2014, based on the KEYNOTE-001 study, the Food and Drug Administration (FDA) approved pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced or unresectable melanoma. Up until now, seven P...
Kaydedildi:
| Yayımlandı: | Pharmaceuticals (Basel) |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8063836/ https://ncbi.nlm.nih.gov/pubmed/33804850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14040288 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|